

Please try another search
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Name | Age | Since | Title |
---|---|---|---|
Ruth Arnon | 89 | - | Head of Scientific Advisory Board |
Mark S. Germain | 71 | 2018 | Chairman of the Board |
Amir Reichman | 46 | 2021 | CEO & Director |
Yael Margolin | 69 | 2020 | Independent Director |
Adi Raviv | 66 | 2020 | Independent Director |
Avner Rotman | 80 | 2005 | Independent Director |
Jay Green | 51 | 2021 | Independent Director |
George H. Lowell | 78 | 2008 | Member of Scientific Advisory Board |
Michel Revel | 85 | - | Member of Scientific Advisory Board |
Morris C. Laster | 58 | 2017 | Independent Director |
Samuel J. Moed | 60 | 2020 | Director |
Matthias Dobbelstein | - | 2022 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review